Toggle light / dark theme

Engineers implanted tiny sensors in rats’ nerves and muscles. Are humans next?

The benefits of the technology for humans, while still largely hypothetical, are promising. The sensors could allow physicians to monitor the health of organs, create new therapies for neurological disorders, and help the physically impaired to control prosthetics.

While chips have been implanted in humans and other animals before, these sensors mark a significant improvement because they are small, wireless, batteryless, and could last in the body for years without degrading, said Michel Maharbiz, the associate professor who devised and studied the sensors alongside neuroscientist Jose Carmena.

“Hopefully the [tiny sensors] demonstrate a new direction for the field, and then you could build the consensus that’s needed to drive these forward,” Maharbiz said.

How Scientists Plan to Grow Cities Out of Living Organisms

Imagine a future where there is no need to cut down a tree and and reshape that raw material into a chair or table. Instead, we could grow our furniture by custom-engineering moss or mushrooms. Perhaps glowing bacteria will light our cities, and we’ll be able to bring back extinct species, or wipe out Lyme disease—or maybe even terraform Mars. Synthetic biology could help us accomplish all that, and more.

That’s the message of the latest video in a new mini-documentary Web series called Explorations, focusing on potentially transformative areas of scientific research: genomics, artificial intelligence, neurobiology, transportation, space exploration, and synthetic biology. It’s a passion project of entrepreneur Bryan Johnson, founder of OS Fund and the payments processing company Braintree.

New microfluidic chip replicates muscle-nerve connection

MIT engineers have developed a microfluidic device that replicates the neuromuscular junction—the vital connection where nerve meets muscle. The device, about the size of a U.S. quarter, contains a single muscle strip and a small set of motor neurons. Researchers can influence and observe the interactions between the two, within a realistic, three-dimensional matrix.

The researchers genetically modified the neurons in the device to respond to light. By shining light directly on the neurons, they can precisely stimulate these cells, which in turn send signals to excite the muscle fiber. The researchers also measured the force the muscle exerts within the device as it twitches or contracts in response.

The team’s results, published online today in Science Advances, may help scientists understand and identify drugs to treat amyotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig’s disease, as well as other neuromuscular-related conditions.

Effective Therapies to Extend Healthy Life May Well be Widely Available for a Decade or More in Advance of Definitive Proof

Fixing one thing only gets you so far, as all the other forms of damage will still, on their own, kill you. Aubrey de Grey of the SENS Research Foundation believes that only small gains in overall life span are possible without addressing all of the causes of aging.


Five years from now, it will be possible to take a trip overseas to have most of the senescent cells that have built up in your tissues cleared away via some form of drug or gene therapy treatment. That will reduce your risk of suffering most age-related diseases, and in fact make you measurably younger — it is a narrow form of rejuvenation, targeting just one of the various forms of cell and tissue damage that cause aging, age-related disease, and ultimately death. I say five years and mean it. If both of the present senescent cell clearance startup companies Oisin Biotechnologies and UNITY Biotechnology fail rather than succeed, and it is worth noting that the Oisin founders have a therapy that actually works in animal studies, while drugs and other approaches have also been shown to both clear senescent cells and extend life in mice, then there will be other attempts soon thereafter. The basic science of senescent cell clearance is completely open, and anyone can join in — in fact the successful crowdfunding of the first Major Mouse Testing Program study earlier this year was exactly that, citizen scientists joining in to advance the state of the art in this field.

Five years from now, however, there will be no definitive proof that senescent cell clearance extends life in humans, nor that it reduces risk of age-related disease in our species over the longer term. There will no doubt be a few more studies in mice showing life extension. There will be initial human evidence that clearance of senescent cells causes short-term improvements in technical biomarkers of aging such as DNA methylation patterns, or more easily assessed items such as skin condition — given how much of the skin in old people is made up of senescent cells — or markers of chronic inflammation. These are all compelling reasons to undertake the treatment, but if you want definite proof of life extension you’ll have to wait a decade or more beyond the point of first availability, as that is about as long as it takes to put together and run academic studies that make a decent stab at quantifying effects on mortality in old people.

Uncertainty is the state of affairs when considering the effects of potentially life-extending therapies on human life span. Consider the practice of calorie restriction, for example, where theory suggests the likely outcome is a few extra years, but certainly not a large number of extra years or else it would be very apparent in epidemiological data. I think that an enterprising individual could, given a good relationship with the Calorie Restriction Society, put together a 20-year or 40-year study to that would — in theory — produce a decent set of data on practitioners and outcomes in the wild. It won’t happen, most likely, because for one the funding isn’t there for such a study, and secondly we’ll be well into the era of widely available rejuvenation therapies along the way. Those calorie restriction practitioners will be taking advantage of treatments to repair the causes of aging just like everyone else.

Crowdfunding Progress Towards a Universal Therapy for All Cancers: an Interview with SENS Research Foundation Scientist Haroldo Silva

An interview with SENS research Dr. Haroldo Silva and his work with ALT Cancer.


As you might have noticed, the SENS Research Foundation is presently asking for your support in a crowdfunding campaign that aims to close in on a universal therapy capable of effectively treating all types of cancer, one based on blocking telomere lengthening. As is often the case, the SENS network is here using philanthropic donations to pick up necessary work that hasn’t been taken on by the rest of the community, so as to unblock progress. The scientist who will lead the work is Haroldo Silva; he has been focused on this particular branch of cancer research for some years now, and below you’ll find a short interview that covers some of his thoughts on the field and on this effort in particular.

I should emphasize that this SENS initiative is an important component in efforts to completely change the way in which the research community approaches the treatment of cancer. The cancer research community suffers from a high level strategy problem: the majority of treatments are only applicable to a small number of cancer types, out of the hundreds of known types, and the majority of new technology platforms under development will be just as expensive to adapt to a different type of cancer as to build in the first place. A much more efficient approach is needed, as there are only so many researchers and only so much funding in the world. As Silva describes below, blocking telomere lengthening is the most efficient of possible better approaches: all cancers must lengthen their telomeres in order to grow, and abuse a small number of target mechanisms in order to do so.

/* */